Hernberg, M <br/><br/>
Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jan 1997 
 - 71-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0923-7534 
<br/><br/><label>Standard No.: </label>10.1023/a:1008293117223  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>CD4-CD8 Ratio<br/>Carcinoma, Renal Cell--drug therapy<br/>Combined Modality Therapy<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Immunologic Factors--therapeutic use<br/>Interferon alpha-2<br/>Interferon-alpha--therapeutic use<br/>Kidney Neoplasms--drug therapy<br/>Life Tables<br/>Male<br/>Middle Aged<br/>Nephrectomy<br/>Recombinant Proteins<br/>Remission Induction<br/>Survival Analysis<br/>Treatment Outcome<br/>Vinblastine--therapeutic use